A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC). (Conference Paper)
Ottensmeier, C. H. H., Jones, T., Sacco, J. J., McCaul, J. A., Brennan, P., Paterson, C., . . . King, E. (2018). A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.6068DOI: 10.1200/JCO.2018.36.15_suppl.6068